Clinical trials: Head Neck Cancer Squamous Cell Recurrent
Head and Neck Cancer
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00337129
- Testing
- eribulin mesylate
- Where
- 139 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission.
- Trial name
- NCT03821272
- Testing
- PepCan
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Arkansas
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to…
- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma
- Trial name
- NCT06568172
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Where
- 206 sites in United States, Australia and 1 more
- Volunteers
- 420 people
- Sponsor
- National Cancer Institute (NCI)
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
The aim of this trial is to examine the addition of docetaxel on disease progression, metastasis and survival of patients otherwise treated with SBRT and cetuximab alone.
- Trial name
- NCT02057107
- Testing
- SBRT, Cetuximab, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Heath Skinner
HNSCC
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with…
- Trial name
- NCT07136545
- Testing
- HCB101, Pembrolizumab
- Where
- 3 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Head and Neck Cancer
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT01009346
- Testing
- RAD001, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
This randomized phase II trial studies how well combination chemotherapy with or without erlotinib hydrochloride works in treating patients with squamous cell carcinoma of the head and neck that has spread to other parts of the…
- Conditions
- Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01064479
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 123 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer, Mucositis
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
RATIONALE: Doxepin hydrochloride may be an effective treatment for oral mucositis pain in patients undergoing radiation therapy with or without chemotherapy.
- Conditions
- Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
- Trial name
- NCT01156142
- Testing
- doxepin hydrochloride
- Where
- 120 sites in United States
- Volunteers
- 155 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms, Head and Neck
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic…
- Trial name
- NCT06062420
- Testing
- Dostarlimab, Belrestotug, Nelistotug
- Where
- 108 sites in United States, Argentina and 18 more
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
The purpose of this study is to test the safety of cabozantinib, at different doses, in combination with cetuximab to find out what effects, if any, this combined treatment has on people with HNSCC.
- Conditions
- Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer
- Trial name
- NCT03667482
- Testing
- Cabozantinib, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2.
- Trial name
- DUAL-HN (NCT07617805)
- Testing
- EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Head and Neck Cancer
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Gene therapy may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have advanced head…
- Trial name
- NCT00009841
- Testing
- EGFR antisense DNA, growth factor antagonist therapy, DC-cholesterol liposome
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Squamous Cell Carcinoma of Esophagus
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.
- Trial name
- NCT05759325
- Volunteers
- 100 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Head and Neck Cancer, Head and Neck Small Cell Carcinoma
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R/M HNSCC, delivered with ultrasound-induced microbubble cavitation, with the goal of optimizing delivery of Pembrolizumab and tumor…
- Conditions
- Head and Neck Cancer, Head and Neck Small Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- NCT07501650
- Testing
- Pembrolizumab, Definity, Ultrasound-Induced Microbubble Cavitation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Thomas Jefferson University
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery.
- Conditions
- Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT03468218
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx
Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer
This pilot clinical trial studies photodynamic therapy using temoporfin before surgery in treating patients with recurrent oral cavity or oropharyngeal cancer.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01718223
- Testing
- photodynamic therapy, therapeutic conventional surgery, laboratory biomarker analysis
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Squamous Cell Carcinoma
Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence
Retrospective observational cohort study investigating Single modality Trans Oral Robotic surgery for primary oropharyngeal cancer: exploring the impact of surgical Margins on local disease recurrence.
- Trial name
- STORM (NCT05065086)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Head and Neck Squamous Cell Carcinoma
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04193293
- Testing
- Duvelisib, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio